| Dr Vivekananda Sharanappa Adike, MD, | |
|
4900 Houston Rd, Florence, KY 41042-4824 | |
| (859) 301-8074 | |
| (859) 301-4945 |
| Full Name | Dr Vivekananda Sharanappa Adike |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 15 Years |
| Location | 4900 Houston Rd, Florence, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689961278 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Elizabeth Ft Thomas | Fort thomas, KY | Hospital |
| St Elizabeth Edgewood | Edgewood, KY | Hospital |
| St Elizabeth Florence | Florence, KY | Hospital |
| St Elizabeth Grant | Williamstown, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group, Inc | 2163326240 | 693 |
| Summit Medical Group, Inc | 2163326240 | 693 |
News Archive
"Regrettably, the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (H.R. 4489) would undermine many of the cost-saving tools used in FEHBP and disrupt prescription drug benefits for 8 million federal employees, retirees, and their families."
A team of researchers at the renowned Scripps Research Institute has discovered two new compounds that prove the existence of new binding sites on HIV protease. Associate Professor C. David Stout, senior author of the study, explained "These results open the door to a whole new approach to drug design against HIV protease," which is an enzyme used by HIV to create new, infectious viral particles.
As millions continue working from home during the pandemic or are required to report to jobs as essential employees, many have raised questions about how these work conditions impact our health - and not just as they relate to COVID-19.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.
› Verified 2 days ago
| Entity Name | Summit Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881026169 PECOS PAC ID: 2163326240 Enrollment ID: O20031120000738 |
News Archive
"Regrettably, the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (H.R. 4489) would undermine many of the cost-saving tools used in FEHBP and disrupt prescription drug benefits for 8 million federal employees, retirees, and their families."
A team of researchers at the renowned Scripps Research Institute has discovered two new compounds that prove the existence of new binding sites on HIV protease. Associate Professor C. David Stout, senior author of the study, explained "These results open the door to a whole new approach to drug design against HIV protease," which is an enzyme used by HIV to create new, infectious viral particles.
As millions continue working from home during the pandemic or are required to report to jobs as essential employees, many have raised questions about how these work conditions impact our health - and not just as they relate to COVID-19.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vivekananda Sharanappa Adike, MD, Po Box 635283, Cincinnati, OH 45263-5283 Ph: (859) 344-5555 | Dr Vivekananda Sharanappa Adike, MD, 4900 Houston Rd, Florence, KY 41042-4824 Ph: (859) 301-8074 |
News Archive
"Regrettably, the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (H.R. 4489) would undermine many of the cost-saving tools used in FEHBP and disrupt prescription drug benefits for 8 million federal employees, retirees, and their families."
A team of researchers at the renowned Scripps Research Institute has discovered two new compounds that prove the existence of new binding sites on HIV protease. Associate Professor C. David Stout, senior author of the study, explained "These results open the door to a whole new approach to drug design against HIV protease," which is an enzyme used by HIV to create new, infectious viral particles.
As millions continue working from home during the pandemic or are required to report to jobs as essential employees, many have raised questions about how these work conditions impact our health - and not just as they relate to COVID-19.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.
› Verified 2 days ago
Karan Motiani, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4900 Houston Rd, Florence, KY 41042 Phone: 859-301-8074 Fax: 859-301-4945 | |
Aishwarya Rushyal Shyamraj, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4900 Houston Rd, Florence, KY 41042 Phone: 859-331-6466 Fax: 859-344-7930 | |
Barbara Marie Okafor, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 7370 Turfway Rd, Florence, KY 41042 Phone: 859-757-4446 Fax: 859-344-1999 | |
Patricia Miles, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7388 Turfway Rd, Florence, KY 41042 Phone: 859-301-9140 Fax: 859-212-5124 | |
Dhanunjay Sarma Boyalakuntla, Internal Medicine Medicare: Medicare Enrolled Practice Location: 4900 Houston Rd, Florence, KY 41042 Phone: 859-301-8074 Fax: 859-301-4945 | |
Philip D Williams, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4900 Houston Road, Florence, KY 41042 Phone: 859-331-6466 Fax: 859-344-7930 | |
Dr. Robert Jeron Strickmeyer, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7388 Turfway Rd, Florence, KY 41042 Phone: 859-525-0005 Fax: 859-525-8806 |